stockportfolio.pro
Stocks / ELV vs REGN
ELV vs REGN
Elevance Health, Inc. and Regeneron Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
ELV is the larger company ($85.0B vs $63.7B). On the fundamentals, REGN grows revenue faster (11.0% vs 10.1%); REGN earns a higher net margin (31.4% vs 2.9%); REGN has the stronger return on equity (14.4% vs 12.9%). Full numbers below — the stronger figure on each row is in green.
| Elevance Health, Inc. (ELV) | Regeneron Pharmaceuticals, Inc. (REGN) | |
|---|---|---|
| Market cap | $85.0B | $63.7B |
| Revenue (latest FY) | $197.58B | $14.34B |
| Net income (latest FY) | $5.66B | $4.50B |
| Revenue growth (5y CAGR) | 10.1% | 11.0% |
| Net margin | 2.9% | 31.4% |
| Return on equity | 12.9% | 14.4% |
| P/E ratio | 16.6 | 14.8 |
| Dividend yield | 1.7% | 0.6% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full ELV vs REGN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ELV's full financials → Open REGN's full financials →More comparisons
Frequently asked questions
Which is bigger, ELV or REGN?
Elevance Health, Inc. is larger by market capitalization — $85.0B versus $63.7B.
Which grows faster, ELV or REGN?
Over the last five fiscal years, Regeneron Pharmaceuticals, Inc. grew revenue faster — 11.0%/yr versus 10.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.